drugset / Trial / NCT02343939
Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)
RandomizedSequentialOpen-labelTreatment
Summary
This study will evaluate the efficacy, safety, and tolerability of entospletinib when administered as monotherapy or in combination with chemotherapy in adults with acute myeloid leukemia (AML).
Timeline
- Start
- 2015-07-01
- Primary completion
- 2018-09-04
- Completion
- 2019-02-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Entospletinib | Small molecule | 400 mg | Oral |
| Subject | Entospletinib | Small molecule | 800 mg | Oral |
| Background | Azacitidine | Other / unclassified | 75 mg/m2 | Intravenous |
| Background | Cytarabine | Small molecule | 100 mg/m2 | Intravenous |
| Background | Daunorubicin | Small molecule | 60 mg/m2 | Intravenous |
| Background | Decitabine | Small molecule | 20 mg/m2 | Intravenous |